Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
Status:
Completed
Trial end date:
2017-03-23
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, crossover study screened 32 subjects with
primary mitochondrial myopathy (PMM) to evaluate the safety, tolerability, pharmacokinetics
(PK), and efficacy of subcutaneous elamipretide in this patient population.